Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThere is no licensed tirzepatide product at a 30 mg dose, and reconstituting tirzepatide in any form is not part of the UK-licensed pathway for this medicine. Tirzepatide is available in the UK as Mounjaro — a pre-filled KwikPen that comes ready to inject, with no mixing, measuring or reconstitution required. If you have come across references to a 30 mg reconstituted vial online or on social media, those relate to compounded or unlicensed preparations that have no legal route through a regulated UK pharmacy. These are prescription-only medicines, and a GPhC-registered prescriber must assess your suitability before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
No. Mounjaro is the only tirzepatide product licensed for use in the UK, and it is manufactured as a ready-to-use subcutaneous injection in a KwikPen. You simply attach a needle, dial the dose and inject, there is nothing to dissolve, dilute or mix. The licensed strengths run from 2.5 mg through to 15 mg, in six steps. A 30 mg dose does not exist within that authorised range.
The idea of reconstituting tirzepatide comes from a practice common in some countries where compounding pharmacies mix medicines from raw active pharmaceutical ingredients. In the UK, that pathway is tightly restricted. The Human Medicines Regulations 2012 and MHRA oversight mean that licensed medicines must be dispensed as manufactured; compounding raw tirzepatide for supply as a weight-loss product sits outside what a UK pharmacy can lawfully do. If a seller is offering reconstituted tirzepatide vials for weight management, that is a red flag, not an alternative option.
The NHS patient information on tirzepatide makes clear that Mounjaro comes as a pre-filled pen and is injected once a week, there is no version of the licensed medicine that requires preparation at home. If you want to understand the full Mounjaro treatment pathway, including how pens are used and stored, that page covers it thoroughly.
This is one of the more understandable misconceptions circulating right now, and it deserves a plain answer rather than a dismissal. In the United States, the FDA approved compounded tirzepatide during a period of drug shortage. Some compounding pharmacies there produced higher-concentration vials (sometimes at doses or concentrations not used in the licensed product) and content about those preparations spread internationally through fitness forums and social media. A 30 mg figure likely comes from that context: a compounded, unlicensed preparation designed around a US shortage that does not apply to the licensed UK supply chain.
UK availability of Mounjaro is separate. Eli Lilly supplies the pens through the authorised UK supply chain, and a regulated pharmacy like ours sources directly from that route. The shortage pressures that drove US compounding do not create a legal basis for equivalent compounding here. More importantly, a reconstituted preparation produced outside a licensed manufacturing environment carries real risks: incorrect concentration, contamination, incorrect sterility, and if anything goes wrong, there is no clinical oversight in place.
The MHRA has published explicit warnings about unsafe fake weight-loss pens sold online, including seizures of counterfeit injectable products. Reconstituted unlicensed vials occupy the same risk territory. You can report a suspect seller via the MHRA Yellow Card scheme, and that is worth doing if you encounter one.
Treatment with Mounjaro starts at 2.5 mg, the tolerability dose. Its purpose is to let your body adjust to the medicine gradually, keeping side effects manageable. From there, a prescriber typically steps the dose up every four weeks, through 5 mg, 7.5 mg, 10 mg, 12.5 mg and finally 15 mg. That 15 mg ceiling is not arbitrary, it reflects the dose range studied in the SURMOUNT clinical programme, on which the MHRA based its authorisation. SURMOUNT-1, published in the New England Journal of Medicine, showed average body-weight reductions of around 20–21% at 15 mg over 72 weeks. Going beyond what the trials demonstrated and the regulator authorised does not produce proportionally better results; it introduces unknown risk.
Prescribers assess each step individually. Dose increases are not automatic, and at nume (sorry, at a clinician-led service like ours) each repeat and each escalation involves a fresh clinical review. There is more on the cost context for Mounjaro if that is part of your thinking, and a broader look at all weight-loss treatment options is on our treatments page. If you are curious how the reconstitution question plays out at lower licensed doses (for academic understanding) the picture is the same: the licensed pen needs none. The 5 mg reconstitution page addresses that specific query, and if you have questions about higher compounded strengths, our pages on how to reconstitute 10 mg tirzepatide and how to reconstitute 60 mg tirzepatide explain the practice in full, alongside our page on how to reconstitute 15 mg tirzepatide, so you can understand why it falls outside legitimate UK supply.
What matters for anyone considering tirzepatide is straightforward: a prescriber reviews your health picture, confirms suitability, and (if appropriate) starts you on the licensed, ready-to-use pen. That is the route that works and the one that keeps you safe.
Two checks cut through most uncertainty quickly. First, look up the pharmacy on the GPhC register at pharmacyregulation.org/registers, every legal online pharmacy dispensing prescription medicines in the UK must be registered, and the register is publicly searchable. Second, ask whether the service requires a genuine clinical consultation before dispensing. A prescriber should be reviewing your full medical history, current medicines and weight, not just ticking boxes.
Red flags are fairly consistent: medicines supplied without a prescription being required, prices dramatically below the market range, sellers operating only through social media, and products described as vials requiring reconstitution. None of those describe licensed Mounjaro. Our clinical team reviews every consultation personally, a named prescriber, not automated software, reads your answers the same day. If you would like to understand how that process works in practice, our FAQs cover the detail. And if you have questions our pages do not answer, get in touch directly.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.